How Pfizer Stock Can Rebound

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer: Market Still Pricing It At Crisis Valuations

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Jim Cramer on Pfizer: “We’ll Find Out if Pfizer’s Going to Be More of a Stock and Less of a Bond Equivalent”

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future ...

Pfizer (PFE): Is There Untapped Value in Today’s Evolving Pharmaceutical Market?

Pfizer (PFE) shares have seen some moderate movement lately, offering investors a chance to reconsider the company’s ...

1 Incredible Reason to Buy Pfizer Stock (PFE) in November

Better still, if interest rates drop, as they're generally expected to over the coming year, the interest income you'll get ...
Blockonomi

Pfizer (PFE) Stock: Pharma Giant Battles Novo Nordisk Over $9 Billion Metsera Deal

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Pfizer: The Storm Has Passed -- Tailwinds Ahead

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.